Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

• DOI: 10.1038/s41467-019-11867-6
• Publication Date: 2019-09-09T14:22:03Z
• Authors: Minsuh Kim; Hyemin Mun; Chang Oak Sung; Eun Jeong Cho; Hye-Joon Jeon; Sung-Min Chun; Da Jung Jung; Tae Hoon Shin; Gi Seok Jeong; Dong Kwan Kim; Eun Kyung Choi; Seong-Yun Jeong; Alison M. Taylor; Sejal Jain; Matthew Meyerson; Se Jin Jang
• Keywords: Organoid; Personalized Medicine; Tumour heterogeneity

Abstract Lung cancer shows substantial genetic and phenotypic heterogeneity across individuals, driving a need for personalised medicine. Here, we report lung organoids normal bronchial established from patient tissues comprising five histological subtypes of non-neoplastic mucosa as in vitro models representing individual patient. The recapitulate the tissue architecture primary tumours maintain genomic alterations original during long-term expansion vitro. cellular components mucosa. respond to drugs based on their alterations: BRCA2-mutant organoid olaparib, an EGFR-mutant erlotinib, EGFR-mutant/MET-amplified crizotinib. Considering short length time establishment drug testing, our newly developed model may prove useful predicting patient-specific responses through trials.